| dc.contributor.author | Sarah Rupprechter | |
| dc.contributor.author | Derek Sloan | |
| dc.contributor.author | Wilna Oosthuyzen | |
| dc.contributor.author | Till Bachmann | |
| dc.contributor.author | Adam Hill | |
| dc.contributor.author | Kevin Dhaliwal | |
| dc.contributor.author | Kate Templeton | |
| dc.contributor.author | Joshua Matovu | |
| dc.contributor.author | Christine Sekaggya Wiltshire | |
| dc.contributor.author | James Dear | |
| dc.date.accessioned | 2021-01-11T13:52:07Z | |
| dc.date.available | 2021-01-11T13:52:07Z | |
| dc.date.issued | 2020 | |
| dc.identifier.uri | https://combine.alvar.ug/handle/1/49871 | |
| dc.publisher | Authorea, Inc. | |
| dc.title | MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for tuberculosis | |
| dc.type | Preprint | |
| dc.identifier.doi | 10.22541/au.159985920.07663977 | |
| dc.identifier.lens | 179-152-103-541-50X |
|
|
|||